Published in BMC Cancer on January 04, 2012
Release and activity of histone in diseases. Cell Death Dis (2014) 1.10
Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer. Onco Targets Ther (2014) 0.94
Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients. World J Gastroenterol (2015) 0.93
Prognostic significance of the preoperative serum C-reactive protein level in patients with stage IV colorectal cancer. Surg Today (2014) 0.88
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer. Br J Cancer (2013) 0.83
Challenges of deciphering gastric cancer heterogeneity. World J Gastroenterol (2015) 0.82
The clinicopathologic importance of serum lactic dehydrogenase in patients with gastric cancer. Dis Markers (2014) 0.79
Upregulation of circulating cytokeratin 20, urokinase plasminogen activator and C-reactive protein is associated with poor prognosis in gastric cancer. Mol Clin Oncol (2015) 0.79
Creation of a federated database of blood proteins: a powerful new tool for finding and characterizing biomarkers in serum. Clin Proteomics (2014) 0.76
Yttrium-90 radioembolization for colorectal cancer liver metastases: a prospective cohort study on circulating angiogenic factors and treatment response. EJNMMI Res (2016) 0.75
Circulating Nucleosomes and Nucleosome Modifications as Biomarkers in Cancer. Cancers (Basel) (2017) 0.75
Expression of CK19 is an independent predictor of negative outcome for patients with squamous cell carcinoma of the tongue. Oncotarget (2016) 0.75
Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancer. Cell Res (2017) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg (2003) 6.04
Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg (1990) 4.36
The blood supply of neoplasms in the liver. Am J Pathol (1955) 4.34
Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol (1986) 2.93
Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest (2005) 2.62
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer (2007) 2.36
Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol (2001) 2.20
Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys (2004) 2.11
Assessing tumor response to therapy. J Nucl Med (2009) 1.95
Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol (2004) 1.88
Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer (2002) 1.65
Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys (1995) 1.50
Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology (2009) 1.44
Clinical use of circulating nucleosomes. Crit Rev Clin Lab Sci (2009) 1.41
Partial irradiation of the liver. Semin Radiat Oncol (2001) 1.35
Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer. Anticancer Res (2001) 1.33
Radiofrequency ablation of unresectable hepatic malignancies: lessons learned. Oncologist (2001) 1.31
Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. Radiographics (2008) 1.25
Clinical relevance of circulating nucleosomes in cancer. Ann N Y Acad Sci (2008) 1.23
Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Clin Cancer Res (2008) 1.22
Radiation microsphere-induced GI ulcers after selective internal radiation therapy for hepatic tumors: an underrecognized clinical entity. Gastrointest Endosc (2009) 1.20
Nucleosomes in serum as a marker for cell death. Clin Chem Lab Med (2001) 1.17
Nucleosomes in serum of patients with benign and malignant diseases. Int J Cancer (2001) 1.13
Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res (2004) 1.08
Heterogeneity in the development of apoptosis in irradiated murine tumours of different histologies. Int J Radiat Biol (1993) 1.05
Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer. Lung Cancer (2008) 1.03
Selective internal radiation therapy with SIR-spheres for the treatment of unresectable colorectal hepatic metastases. Cardiovasc Intervent Radiol (2009) 1.01
The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer. Br J Cancer (2006) 1.00
Prognostic factors after cryotherapy for hepatic metastases from colorectal cancer. Ann Surg (1998) 0.99
Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol (2001) 0.98
Yttrium-90 radioembolization for liver malignancies: prognostic factors associated with survival. J Vasc Interv Radiol (2009) 0.98
Radiofrequency ablation after selective internal radiation therapy with Yttrium90 microspheres in metastatic liver disease-Is it feasible? Eur J Radiol (2009) 0.97
Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using (90)Yttrium resin-microspheres. Eur Radiol (2006) 0.96
Tumour-to-normal uptake ratio of 90Y microspheres in hepatic cancer assessed with 99Tcm macroaggregated albumin. Br J Radiol (1997) 0.96
Early and specific prediction of the therapeutic efficacy in non-small cell lung cancer patients by nucleosomal DNA and cytokeratin-19 fragments. Ann N Y Acad Sci (2006) 0.93
Diagnostic relevance of circulating biomarkers in patients with lung cancer. Cancer Biomark (2010) 0.91
Nucleosomes in colorectal cancer patients during radiochemotherapy. Tumour Biol (2006) 0.89
Nucleosomes in pancreatic cancer patients during radiochemotherapy. Tumour Biol (2005) 0.88
Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancer. Cancer Biomark (2010) 0.88
Circulating apoptotic markers in the management of non-small cell lung cancer. Cancer Biomark (2010) 0.87
Circulating nucleosomes and cytokeratin 19-fragments in patients with colorectal cancer during chemotherapy. Anticancer Res (2005) 0.84
RADIOACTIVE ISOTOPES FOR ADJUVANT CANCER THERAPY; ANIMAL EXPERIMENTATION AND PRELIMINARY RESULTS IN HUMAN APPLICATION. Arch Surg (1964) 0.81
Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases. Ann Surg Oncol (2010) 0.79
[Developments and perspectives in radioablative techniques]. Radiologe (2007) 0.79
Effects of hepatic arterial yttrium-90 microsphere administration alone and combined with regional bromodeoxyuridine infusion in dogs. Cancer Res (1987) 0.77
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging (2010) 7.82
Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med (2010) 4.32
Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91
Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol (2007) 3.25
Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res (2004) 2.81
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging (2014) 2.79
Magnetic resonance colonography for the detection of colorectal neoplasia in asymptomatic adults. Gastroenterology (2013) 2.71
Methylation of serum DNA is an independent prognostic marker in colorectal cancer. Clin Cancer Res (2006) 2.13
EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging (2010) 2.09
Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation (2013) 2.08
Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol (2011) 1.85
MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One (2011) 1.79
Sixty-four slice spiral CT angiography does not predict the functional relevance of coronary artery stenoses in patients with stable angina. Eur J Nucl Med Mol Imaging (2006) 1.70
Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology (2006) 1.58
Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys (2009) 1.51
EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging (2009) 1.49
FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging (2007) 1.47
Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European 123I-FP-CIT SPECT database. Eur J Nucl Med Mol Imaging (2012) 1.47
Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease. Clin Chim Acta (2010) 1.47
Long-term assessment of striatal dopamine transporters in Parkinsonian patients with intrastriatal embryonic mesencephalic grafts. Eur J Nucl Med Mol Imaging (2006) 1.46
EANM procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals, version 2. Eur J Nucl Med Mol Imaging (2009) 1.45
Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: pretreatment levels or kinetics during chemotherapy? Onkologie (2007) 1.42
Clinical use of circulating nucleosomes. Crit Rev Clin Lab Sci (2009) 1.41
Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer? World J Urol (2012) 1.39
Tumor markers in breast cancer- European Group on Tumor Markers recommendations. Tumour Biol (2005) 1.36
Soluble MICA in malignant diseases. Int J Cancer (2006) 1.36
Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med (2006) 1.33
Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. J Nucl Med (2005) 1.32
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem (2010) 1.32
Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med (2009) 1.31
Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol (2013) 1.29
Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging (2004) 1.28
Cell-free DNA in serum and plasma: comparison of ELISA and quantitative PCR. Clin Chem (2005) 1.27
Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort. PLoS One (2012) 1.25
Soluble NKG2D ligands: prevalence, release, and functional impact. Front Biosci (2008) 1.24
Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals. Scand J Gastroenterol (2010) 1.24
Clinical relevance of circulating nucleosomes in cancer. Ann N Y Acad Sci (2008) 1.23
Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer. Clin Cancer Res (2008) 1.22
Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma. Cancer Epidemiol (2012) 1.20
OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer. Clin Cancer Res (2008) 1.20
European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging (2012) 1.19
Nucleosomal DNA fragments in autoimmune diseases. Ann N Y Acad Sci (2006) 1.16
Methylation of NEUROG1 in serum is a sensitive marker for the detection of early colorectal cancer. Am J Gastroenterol (2011) 1.16
Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.15
Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord (2009) 1.15
Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery (2005) 1.15
Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J Vasc Interv Radiol (2008) 1.14
Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation (2003) 1.14
Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA. Cancer Immunol Immunother (2006) 1.11
Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. Br J Psychiatry (2009) 1.09
Multi-detector row CT angiography of the brain at various kilovoltage settings. Radiology (2004) 1.09
Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res (2004) 1.08
Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? Cancer (2002) 1.08
Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma. Int J Urol (2012) 1.07
The impact of reconstruction method on the quantification of DaTSCAN images. Eur J Nucl Med Mol Imaging (2010) 1.06
Comparison of spiral multidetector CT angiography and myocardial perfusion imaging in the noninvasive detection of functionally relevant coronary artery lesions: first clinical experiences. J Nucl Med (2005) 1.05
Circulating microparticles in breast cancer patients: a comparative analysis with established biomarkers. Anticancer Res (2008) 1.04
Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder. Biol Psychiatry (2003) 1.04
Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer. Lung Cancer (2008) 1.03
Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy. Tumour Biol (2011) 1.03
Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol (2008) 1.03
Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study. Crit Care (2014) 1.02
Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy. Int J Cancer (2013) 1.02
Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. Tumour Biol (2010) 1.02
Does combined imaging of the pre- and postsynaptic dopaminergic system increase the diagnostic accuracy in the differential diagnosis of parkinsonism? Eur J Nucl Med Mol Imaging (2007) 1.02
Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy. Tumour Biol (2012) 1.01
Selective internal radiation therapy with SIR-Spheres in patients with nonresectable liver tumors. Cancer Biother Radiopharm (2005) 1.01
Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients. Int J Cancer (2013) 1.00
Chemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinoma. Digestion (2008) 0.99
CT-guided radiofrequency ablation in patients with hepatic metastases from breast cancer. Cardiovasc Intervent Radiol (2008) 0.98
D2 receptor occupancy during high- and low-dose therapy with the atypical antipsychotic amisulpride: a 123I-iodobenzamide SPECT study. J Nucl Med (2005) 0.98
The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses. Clin Chem Lab Med (2011) 0.98